In the afternoon session, the 'Ways and means' by which appropriate literature could be provided were discussed under the chairmanship of Katharine Whitehorn (The Observer) against the background of the likely change to original medicine pack dispensing during 1987. Dr Andrew Herxheimer (Editor, Drug and Therapeutics Bulletin) spoke about the possible methods of providing information during the medical consultation, when the pharmacist dispensed the medicine, and through the patient package insert (PPI). He suggested that an aidememoire could be incorporated in the Data Sheet Compendium which would jog the doctor's memory about the important things a patient needed to know in order to comply with treatment, and also to add to the data sheet suggested contents for an appropriate PPI. He also provided a short list of the sort of mandatory items that one needed to tell the patient about the medicine, including in some instances important precautions about taking the drugs when driving or operating machinery, and whether there were any interactions with alcohol or other drugs.
Professor Michael Drury (Professor of General Practice, Birmingham) stressed the importance of the face-to-face interview with the patient and the need to convey to the patient how to use the drug properly. He regarded written material as a reinforcement for the information imparted at consultation. He was concerned with the need to educate general practitioners, not only about the proper use of medicines but also when medicines could be avoided, and how to explain this to the patient.
Mr John Balmford (Pharmaceutical Society of Great Britain) emphasized the pharmacist's role and the importance of labelling medicine containers with essential information, such as how and when to take the medicine, when the medicine was likely to impair performance and to keep all medicines out of the reach of children. He explained how the pharmacist could do much to help special groups of patients, such as the elderly, to understand and comply with their medical regimen through the use of special reminder containers. He felt that the pharmacist should consider visiting the patient at home to see how the medicines were being taken in practice and at the same time identify old stock (and large medicine stores) which ought to have been disposed of.
Finally, Mr Bill Gerard (Association of the British Pharmaceutical Industry) explained that by the beginning of 1987 it was anticipated that manufacturers' packs would be passed directly on to patients and the contents no longer transferred to chemists' tins and bottles. This type of original pack dispensing would enable manufacturers to place package inserts into the containers giving appropriate information on proper use. The ABPI had consulted a number of consumer and professional organizations to determine their needs and to obtain advice. A 'champion' was now needed to lead the way and progress developments for the benefit of all. The expenditure for patient information would probably have to be borne by the pharmaceutical industry. If so, they would wish to have a substantial say in the content.
During the discussion it was suggested that the Government should provide finance for the creation of appropriate drug information, and this would help to ensure that such information was provided by an independent source or committee and hence reduce the tendency for pharmaceutical companies to engage in quasi-promotional activity. Other discussants considered that it was a counsel for perfection to think that the bulk of the medical profession and pharmacists would be able to give patients the information they required. If nothing else, time constraints would make this largely impossible, but in addition many practitioners were not alive to patient needs. Representatives of consumer associations testified to the total inadequacy of the verbal information they were given and how dangerous this could be at times. It was concluded that the major partners in the creation of patient literature would have to be the pharmaceutical industry, who would be responsible for its production, and the patient (represented by the consumer organizations) who needed it. The idea behind the French joint committee had much to recommend it, and an early start should be made to produce literature for the medicines in most common use. The advice of clinical pharmacologists, general practitioners and pharmacists should be sought on the content of this literature. 
D M Burley

Immunology of vascular endothelial cells
Endothelial cells provide a selectively permeable barrier, and a non-thrombogenic surface throughout the vasculature. The integrity of this cell layer in normal individuals prevents platelet deposition, and influences granulocyte emigration, accumulation of lipids and other functions. Many different types of inflammatory reaction induce changes in the interaction between blood constituents and endothelial cells, leading to emigration of cells and movement of fluid into tissue spaces. Although the morphological appearances of blood cell interactions with vascular endothelial cells have been documented for many years, the nature of these interactions and their regulation have only recently begun to be understood. This is possible mainly because endothelial cells can now be grown in vitro, and a wide range of new reagents and techniques are being applied to the study of vascular endothelium. This meeting was held to review research in some of these areas, and to discuss recent work on the involvement of endothelial cells in inflammation, graft rejection, cellmediated immunity and the histogenesis of vascular tumours. 0141-0768/86/ 030178-04/$02.00/0 0 1986 The Royal Society of Medicine Endothelial cell injury and interactions with granulocytes Dr John Gordon (Harrow) reviewed the interaction of endothelium with granulocytes and mediators produced by them. Electron micrographs showed spherical granulocytes apparently rolling along the surface of the vascular endothelium. After adhering to the surface of the endothelial cells they migrated underneath, and spread out. In vitro, neutrophils in suspension adhered to monolayers of endothelial cells without the requirement for additional stimuli, and again spread out beneath the monolayer'.
Granulocyte adhesion to and migration through endothelium at certain sites is a normal physiological phenomenon, which is greatly increased during an inflammatory response. However, under some circumstances activated granulocytes can cause endothelial damage. The mechanisms responsible are still under investigation, but it appears that proteases (e.g. elastase, cathepsin G) and oxygen products (e.g. H202 or radicals derived therefrom) are involved2'-. Depending on the intensity of the stimulus, the endothelial responses range from mild (e.g. stimulation of prostaglandin production, changes in energy metabolism) to severe (release of cytoplasmic proteins, loss of cell viability).
C5a and vascular permeability
Dr Tim Williams (London) described experimental work on the way the 74 amino acid polypeptide C5a induces oedema formation. Rabbits were injected intradermally with zymosan (yeast cell walls) to mimic a local microbial infection, and plasma protein leakage from skin microvessels was monitored using intravenous '25I-albumin5. Zymosan activates complement in extravascular tissue fluid and generates C5a. Both rabbit and human C5a were found to increase microvascular permeability with a potency far higher than that of histamine. This permeabilityincreasing activity of C5a was not lost after cleavage of C terminal arginine by the action of plasma carboxypeptidase N. The oedema response to zymosan was suppressed by the prostaglandin synthesis inhibitor, indomethacin, and exogenous C5a required the addition of a prostaglandin (El, E2 or I2) in order to induce oedema in the skin. It appears that zymosan stimulates the generation of a prostaglandin in the skin and this substance acts synergistically with C5a to induce oedema. This phenomenon is probably dependent on the vasodilator activity of the prostaglandin as vasodilator peptides, vasoactive intestinal polypeptide (VIP) and calcitonin gene-related peptide (CGRP) were also found to enhance C5a-induced oedema. The oedema responses to C5a in the skin appeared to be visually similar to those induced by histamine and bradykinin, using extravasation of blue dye as an index (each mediator in combination with PGE2). However, responses to C5a were abolished by depleting circulating neutrophils, whereas responses to the other mediators were unaffected. Thus, C5a is thought to trigger a rapid interaction between neutrophils and venular endothelial cells, which results in plasma protein leakage.
The results of experiments in the skin were supported by further experiments in the rabbit peritoneal cavity where injection of zymosan resulted in the extravascular generation of C5a (measured using a specific radioimmunoassay), plasma protein leakage and neutrophil accumulation6. Similar mechanisms may be involved in oedema formation during flare-up reactions in the rheumatoid joint, which are characterized by immune complex formation, complement consumption and massive neutrophil accumulation.
Antigens on endothelial cells Dr William Buurman (Maastricht, Holland) described experimental work on dog endothelial cells, from the point of view of their role in graft rejection and vascular injury. He showed that in vitro generated cytotoxic lymphocytes were able to kill cultured endothelial cells. In both the afferent phase (stimulation) and the efferent phase (cytotoxicity) of the cytotoxic T cell response in vitro, different antigens were found to be recognized on arterial and venous endothelial cells7. The findings demonstrate phenotypical differences between arterial and venous endothelial cells. Endothelial cells were able to replace other types of antigen-presenting cells. Endothelial cells were shown to be capable of presenting foreign alloantigens to syngeneic lymphocytes in vitro'. Furthermore, endothelial cells could present alloantigens present on the endothelial cells to allogeneic lymphocytes, a process important in graft rejection and graft-versus-host disease. In culture, canine endothelial cells did not express class II major histocompatibility (MHC) antigens, but they were induced to do so by lymphokines. The production of these lymphokines in vitro was inhibited by cyclosporin A (CsA), whereas CsA was shown not to affect the induction of MHC-class II antigens by lymphokines. In vivo experiments demonstrated the lymphokine dependence of MHCclass II antigens on capillary endothelium, since CsA treatment of otherwise healthy dogs abrogated MHC-class II expression on capillary endothelial cells9.
Professor John Fabre (East Grinstead) discussed the presence of MHC antigens in renal and cardiac allografts, and their role in regulating immune responses. The degree of MHC class II antigen expression on unstimulated endothelial cells varies in different species. They are found on normal human endothelial cells but not on normal rat endothelial cells, where further stimulation is required for their expression. In contrast, dendritic cells which are widespread in tissues, except for the central nervous system, express these antigens strongly in every species so far studied'0' I'. In rats, dendritic cells are replaced within a few weeks, so that they become of host type not long after transfer into an intermediate recipient. The importance of the vascular endothelium in rats has been demonstrated in experiments in which renal allografts were transplanted via an intermediate host to thirdparty hosts, in whom the response was directed against the antigens present on the endothelial cells'2. Although endothelial cells in the rat do not normally express class II MHC antigens, in man these antigens are present on the vascular endothelium and may induce cytotoxic responses, and act as targets for immune tissue injury. The persistence of endothelial cell membrane antigens may explain why long-term immunosuppression is required in man to prevent allograft rejection, in contrast to the rat in which short courses can result in permanent graft acceptance.
During the initial period of a few weeks after grafting, endothelial cells in the rat may be induced to express class II MHC antigens. This was shown in rat cardiac allografts"3. Induction of expression affects both endocardial and myocardial cells. It is possible that the endothelial cells act as accessory cells in the induction of allergic damage to myocardial cells. Inflammatory delayed type hypersensitivity responses cause tissue damage and gamma-interferon release; the gamma-interferon induces MHC class II antigen expression; and the newly expressed class II antigens stimulate further delayed type hypersensitivity responses, thus completing the cycle of injury. In the kidney, renal tubules express class II MHC antigens, and this may be important in protecting the renal tract against infections.
Other endothelial cell membrane antigens In addition to the MHC antigens, blood group antigens, and other membrane constituents found in other cell membranes, endothelial cells have been found to express a variety of membrane antigens which are preferentially expressed in blood and lymphatic vessels. Although some autoantibodies against endothelial cells have been found in human diseases such as systemic lupus erythematosus and hyperacute allograft rejection, it is only recently that monoclonal antibodies have been produced against endothelial cell membrane antigens. Several laboratories have now reported successful production of these reagents, although little is known about the nature of the structures they bind to. This work was reviewed by Dr Christopher Spry (London) . Antibody En3 was one of the first of these antibodies to be described. It was produced by immunizing mice with human umbilical vein endothelial cells. This antibody binds to the surface of endothelial cells in most parts of the body, and shows limited cross-reaction with syncytiotrophoblast, but not other cells"4. Subsequently, four other antibodies which do not bind to leukocytes (distinguishing them from many other types of cross-reacting antibodies which have also been described recently) have been studied. Antibody En4 detected a labile antigen which was able to demonstrate the presence of endothelial cells in both blood and lymphatic tissues, after mild fixation by a periodate, lysine paraformaldehyde technique. As a monoclonal antibody PAL-E did not stain lymphatic endothelium, a combination of these antibodies was able to show that Kaposi's sarcoma, and most angiosarcomas, were probably of lymphatic endothelial cell origin. Regional differences in endothelial cells were shown by differences in the expression of antigens recognized by antibodies En5 and En6. These reagents, combined with the Ulex europaeus agglutinin, factor VIII-related antigen, and laminin, provide a wide range of different approaches to studying regional expression of endothelial heterogeneity, which may be important in the localization of different diseases.
Endothelium in delayed hypersensitivity reactions Dr Philip Askenase (Yale, USA) discussed the interrelationship between the vasculature and delayed hypersensitivity reactions. An early event in delayed hypersensitivity in mice is the release of 5-hydroxytryptamine by mast cells, and other sources of serotonin. This binds to endothelial cells in postcapillary venules, causing the formation of gaps through which Lyl + MHC-restricted T lymphocytes migrate and interact with antigens in the tissue. Production of chemoattractants and lymphokines follows, inducing inflammatory cells to marginate and localize in tissues.
These responses appear to be initiated by vasoactive factors induced by antigen-specific Lyl + T lymphocytes'5. These factors may sensitize various sites in the body where the response can be elicited subsequently.
Conclusions
This meeting brought together a number of groups working on endothelial cells. The common basis for the work described here was the view that endothelial cells are a central component of several different types of immune response, including complement-mediated reactions, acute and chronic inflammatory injury to tissues, allograft reaction and delayed hypersensitivity responses. This widespread involvement of endothelial cells in these processes indicates that they may have a central role in many different diseases, not simply as selectively permeable structures lining vessels, but as sites in which the immune response is initiated or expressed through alterations in permeability, cell margination and tissue injury. It was agreed that the wide range of techniques now being brought to bear on the study of endothelial cells has shown that they are more heterogeneous, and have a greater capacity to alter their properties in response to stimulation, than was previously known. These important findings have many implications which are expected to provide a major stimulus for further experimental and clinical work into the properties of vascular endothelial cells in disease. Species differences in structure, function and metabolism have attracted attention in the last twenty years and the liver is frequently a key to these differences. The need to extrapolate from animal data in the fields of drug and chemical safety evaluation and of risk assessment has posed several questions concerning species differences. In addition, it is clear that animal models of human diseases may facilitate therapeutic research and that the detailed study of disease processes in animals may provide clues to the aetiology of some human diseases.
A McCartney
Species differences in structure and function Some anatomical species differences were described by Professor R J Roberts in relation to fish. Some species of fish, such as cod and herring, have a simple liver resembling that of higher animals, whilst many tropical fish, catfish and salmon have an hepatopancreas, with pancreatic tissue distributed along the major veins within the liver parenchyma. Fish have accumulations of melanomacrophages in the liver which are part of the APUD sy §tem and may play some role in metabolic detoxification of xenobiotics, as they increase in number following treatment with the nitrosamines.
Another species difference in structure and function between fish and higher animals is that in fish Kupffer cells are not present in the liver, but instead the atrium of the heart is lined by Kupffer-like cells. The result is that bacteria and toxins which would accumulate in the liver of higher animals, and would do no more than cause minimal focal necrosis, may be rapidly fatal in the fish due to myocardial necrosis.
Some functional species differences also may be of significance. For example, fish fed on rancid fish waste may accumulate fat in many tissues including the liver, which becomes very friable and readily ruptures. Like man, the fish is what he eats, and this provides the fascinating prospect of using diet to 'lipid tailor' the fish so that its flesh becomes high in polyunsaturated fats and consequently highly marketable as a 'health food'.
Species differences in metabolism
Species differences in the metabolism of xenobiotics were described by Professor R L Smith. The basic pathways are remarkably constant across all species and can be divided into the Phase I and Phase II reactions. Phase I reactions are basically those of oxidation, reduction and hydrolysis and are far more important than Phase II in determining the biological activity of a chemical. The reactions are numerous and diverse, but rarely differ qualitatively between species. However, apparently minor differences may determine whether a compound is a carcinogen or not. For example, N2-fluorenylacetamide requires metabolic activation by Nhydroxylation in order to become a proximate carcinogen. In man, around 14% of a dose will be N-hydroxylated, whilst 25-30% undergoes 7-Chydroxylation. Thus a proximate carcinogen is formed in man. In the guinea-pig, 73% of the dose undergoes 7-C-hydroxylation and none is N-hydroxylated, thus explaining why N2-fluorenylacetamide is not a carcinogen in the guinea-pig.
Even within a species, there may be considerable strain differences in the metabolic pathways involved. For example, the DA rat has impaired oxidative metabolism of several compounds, such as phenacetin and hexobarbitone, whereas the oxidative metabolism of other drugs is unaltered, e.g. tolbutamide or acetanilide.
The Phase II reactions show more qualitative interspecies variation, with some species forming unusual conjugates, e.g. the rat forms aspartic acid and serine conjugates of DDA (a metabolite of DDT). 0141/0768/86/ 030181-03/$02.00/0 © 1986 The Royal Society of Medicine
